Adage Capital Partners GP L.L.C. Purchases 92,136 Shares of Insulet Corporation $PODD

Key Points

• Adage Capital Partners GP L.L.C. increased its stake in Insulet Corporation by 59.3% during the first quarter, now owning a total of 247,636 shares worth approximately $65 million.
• Multiple institutional investors, including Vanguard Group and American Century Companies, also expanded their holdings in Insulet, showcasing strong interest in the company.
• Analysts maintain a consensus rating of “Moderate Buy” for Insulet, with an average price target of $332.71, following a positive earnings report that exceeded expectations.

Adage Capital Partners GP L.L.C. increased its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 59.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 247,636 shares of the medical instruments supplier's stock after acquiring an additional 92,136 shares during the quarter. Adage Capital Partners GP L.L.C. owned approximately 0.35% of Insulet worth $65,032,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of PODD. Captrust Financial Advisors boosted its position in shares of Insulet by 24.1% in the fourth quarter. Captrust Financial Advisors now owns 2,185 shares of the medical instruments supplier's stock worth $570,000 after buying an additional 425 shares during the period. Brevan Howard Capital Management LP acquired a new stake in shares of Insulet in the fourth quarter worth $305,000. Driehaus Capital Management LLC boosted its position in shares of Insulet by 120.3% in the fourth quarter. Driehaus Capital Management LLC now owns 99,886 shares of the medical instruments supplier's stock worth $26,077,000 after buying an additional 54,539 shares during the period. Frontier Capital Management Co. LLC boosted its position in shares of Insulet by 21.8% in the fourth quarter. Frontier Capital Management Co. LLC now owns 110,170 shares of the medical instruments supplier's stock worth $28,762,000 after buying an additional 19,692 shares during the period. Finally, Ethic Inc. boosted its position in shares of Insulet by 44.3% in the fourth quarter. Ethic Inc. now owns 5,462 shares of the medical instruments supplier's stock worth $1,426,000 after buying an additional 1,678 shares during the period.

Insulet Stock Performance

Shares of Insulet stock traded up $1.96 during trading on Friday, reaching $348.43. The company's stock had a trading volume of 498,473 shares, compared to its average volume of 584,368. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The business's fifty day moving average price is $307.55 and its 200-day moving average price is $289.86. The firm has a market cap of $24.53 billion, a price-to-earnings ratio of 105.91, a price-to-earnings-growth ratio of 2.92 and a beta of 1.36. Insulet Corporation has a one year low of $211.27 and a one year high of $350.00.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm's revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

PODD has been the subject of several recent analyst reports. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Citigroup reissued a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Barclays lifted their price objective on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $332.71.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.